skip to Main Content
DNA IRBM

CHDI Foundation extends collaboration with IRBM to accelerate development of Huntington’s disease therapeutics

Pomezia, Italy, November 19th 2018 – IRBM, a global contract research organization (CRO), has strengthened its position in neurodegenerative disease research following an extension of its long-standing collaboration with CHDI Foundation, a nonprofit biomedical research organization exclusively dedicated to collaboratively developing therapeutics that substantially improve the lives of those affected by Huntington’s disease (HD).

Global Growth New Appointments IRBM

IRBM continues global growth with two new appointments

IRBM continues global growth with two new appointments

Pomezia, Italy, May 31, 2018 –  IRBM, a global Contract Research Organization, has recruited two new members of staff as part of its global growth strategy. Carlo Toniatti, M.D., Ph.D., has been appointed as the Chief Scientific Officer, bringing more than two decades of drug development and discovery experience to the role where he will oversee scientific strategy, and Heidi Kingdon-Jones has been recruited as the Global VP of Sales and Marketing, to drive forward IRBM’s continued global expansion.

Heroes Of Chemistry 2017 IRBM

The American Chemical Society Honors IRBM Leading Scientists as Heroes of Chemistry 2017

WASHINGTON, D.C., August 20, 2017 – At a ceremony prior to the American Chemical Society fall meeting, the ACS inducted Dr. Vincenzo Summa and Dr. Steven Harper, respectively the Vice President of Drug Discovery and the Head of Medicinal Chemistry at IRBM Science Park S.p.A., into its scientific Hall of Fame as Heroes of Chemistry, 2017. The program recognizes scientists whose innovative work in chemistry and chemical engineering led to commercial products that benefit the world.

Major HBV Agreement With Lombardy IRBM

IRBM’s Promidis Announces Major HBV Agreement with Lombardy

MILAN, June 20, 2017 – IRBM announced today that a scientific consortium led by its subsidiary Promidis received a 5.6 million euro grant from the Italian region of Lombardy to discover and develop innovative cures for chronic hepatitis B, a disease which still affects a significant portion of the world population, despite the availability of a vaccine. Chronic hepatitis B is a significant burden on national health systems, and can lead to severe complications, especially in children.

CNCCS Joins PRONAT Project IRBM

CNCCS Joins PRONAT Project

VITERBO (VT), June 30, 2016 – IRBM’s CNCCS consortium joined the Università della Tuscia, the Italian National Research Council (CNR), and the Italian Department of Instruction, University and Research (MIUR) in announcing the joint PRONAT project, aimed at identifying bioactive agents of animal or plant origin.

IRBM News

IRBM Presents Final Results at AICI Meeting

ROME, June 24, 2015 – The final results of the Italian- and European-funded AICI project (Approcci Innovativi per il Controllo delle Infezioni, Innovative Approaches for Infection Control), activated in 2013 and carried out by a network of biotech companies such as IRBM Science Park S.p.A., Angelini, Ylichron and IBN Savio, were presented at a final workshop at the Angelini Research Center in St. Palomba (RM).

Back To Top